• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

城市内艾滋病病毒诊所的心血管事件与包含阿巴卡韦与替诺福韦酯的抗逆转录病毒治疗方案的关系。

Cardiovascular Events in an Inner-City HIV Clinic and Relationship to Abacavir Versus Tenofovir Disoproxil Fumarate-Containing Antiretroviral Regimens.

机构信息

Department of Family Medicine, Maple Leaf Medical Clinic, Toronto, Ontario, Canada.

Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

出版信息

AIDS Res Hum Retroviruses. 2021 Jan;37(1):44-53. doi: 10.1089/AID.2020.0053. Epub 2020 Nov 2.

DOI:10.1089/AID.2020.0053
PMID:33019803
Abstract

Following cardiovascular events (CVE) among people living with HIV (PLWH) is essential. Abacavir (ABC)'s impact on CVE challenges clinicians. We characterized CVE at our HIV clinic associated with ABC versus tenofovir disoproxil fumarate (TDF). This was a retrospective study of PLWH who started combination antiretroviral therapy with no prior CVE. Patients were evaluated as antiretroviral naive or antiretroviral experienced. Regimens included the following: always-ABC, always-TDF, first-ABC-switched-to-TDF, and first-TDF-switched-to-ABC regimens. Frequencies, rates, and Poisson regression were used to analyze CVE (cardiovascular/cerebrovascular) and were stratified with an cutoff of before or after January 1, 2009. 1,440/2,852 patients were antiretroviral naive; 658 on always-ABC regimens, 1,186 on always-TDF regimens, 737 first-ABC-switched-to-TDF regimens, and 271 first-TDF-switched-to-ABC regimens. Seventy seven CVE occurred overall [16 naive vs. 61 experienced ( < .0001)]. Sixty events were cardiovascular and 17 cerebrovascular ( < .0001). Sixty-nine CVE occurred before 2009 and eight after ( < .0001). There were 5.65 CVE-per-1,000-years [95% confidence interval (CI) 3.23-9.87] in the always-ABC, 1.95 CVE-per-1,000-years (95% CI 1.08-3.51) in the always-TDF, 2.01 CVE-per-1,000-years (95% CI 1.14-3.56) in the ABC-switched-to-TDF, and 1.82 CVE-per-1,000-years (95% CI 0.77-4.30) in TDF-switched-to-ABC ( <.01). Multivariable Poisson regression incidence rate ratios (IRRs) revealed that being on ABC-only (IRR 2.89; 95% CI 2.13-3.94), age (IRR 1.06 per year; 95% CI 1.04-1.07), and smoking (IRR for current 2.81; 95% CI 1.97-3.99; IRR for former 2.49; 95% CI 1.72-3.61) increased risk of CVE. Thus, in our clinic, CVE rates were increased in those on ABC and adds to the body of literature suggesting concern.

摘要

对 HIV 感染者(PLWH)进行心血管事件(CVE)监测至关重要。阿巴卡韦(ABC)对 CVE 的影响给临床医生带来了挑战。我们在我们的 HIV 诊所对与 ABC 相关的 CVE 进行了特征描述,与替诺福韦二吡呋酯(TDF)进行了比较。这是一项回顾性研究,纳入了从未发生过 CVE 的开始联合抗逆转录病毒治疗的 PLWH。患者被评估为抗逆转录病毒初治或抗逆转录病毒经验丰富。方案包括以下几种:始终使用 ABC、始终使用 TDF、首先使用 ABC 转换为 TDF 以及首先使用 TDF 转换为 ABC。使用频率、比率和泊松回归来分析 CVE(心血管/脑血管),并使用 2009 年 1 月 1 日之前或之后的时间点进行分层。1440/2852 名患者为抗逆转录病毒初治;658 名患者使用 ABC 方案,1186 名患者使用 TDF 方案,737 名患者首先使用 ABC 转换为 TDF 方案,271 名患者首先使用 TDF 转换为 ABC 方案。总体发生了 77 例 CVE[16 例初治与 61 例经验丰富( < .0001)]。60 例为心血管事件,17 例为脑血管事件( < .0001)。69 例 CVE 发生在 2009 年之前,8 例发生在之后( < .0001)。在 ABC 方案中,每 1000 年发生 5.65 例 CVE[95%置信区间(CI)3.23-9.87];在 TDF 方案中,每 1000 年发生 1.95 例 CVE[95%CI 1.08-3.51];在 ABC 转换为 TDF 方案中,每 1000 年发生 2.01 例 CVE[95%CI 1.14-3.56];在 TDF 转换为 ABC 方案中,每 1000 年发生 1.82 例 CVE[95%CI 0.77-4.30]( <.01)。多变量泊松回归发病率比(IRR)显示,仅使用 ABC(IRR 2.89;95%CI 2.13-3.94)、年龄(IRR 每年 1.06;95%CI 1.04-1.07)和吸烟(当前吸烟的 IRR 为 2.81;95%CI 1.97-3.99;以前吸烟的 IRR 为 2.49;95%CI 1.72-3.61)会增加 CVE 的风险。因此,在我们的诊所中,使用 ABC 的患者 CVE 发生率增加,这增加了文献中对 ABC 相关 CVE 风险的关注。

相似文献

1
Cardiovascular Events in an Inner-City HIV Clinic and Relationship to Abacavir Versus Tenofovir Disoproxil Fumarate-Containing Antiretroviral Regimens.城市内艾滋病病毒诊所的心血管事件与包含阿巴卡韦与替诺福韦酯的抗逆转录病毒治疗方案的关系。
AIDS Res Hum Retroviruses. 2021 Jan;37(1):44-53. doi: 10.1089/AID.2020.0053. Epub 2020 Nov 2.
2
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.含替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯的固定剂量单片复方制剂治疗初治 HIV-1 感染的疗效和安全性:一项随机对照试验的荟萃分析。
Int J Infect Dis. 2020 Apr;93:108-117. doi: 10.1016/j.ijid.2020.01.035. Epub 2020 Jan 25.
3
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.从富马酸替诺福韦二吡呋酯制剂转换为替诺福韦艾拉酚胺制剂对 HIV 感染者血脂谱、体重增加和心血管风险评分的影响。
BMC Infect Dis. 2021 Sep 6;21(1):910. doi: 10.1186/s12879-021-06479-9.
4
Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.与阿巴卡韦/拉米夫定相比,替诺福韦酯/恩曲他滨与低钙血症风险较高相关——一项德国队列研究的结果
Int J STD AIDS. 2019 Apr;30(5):447-452. doi: 10.1177/0956462418815022. Epub 2019 Jan 10.
5
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.从替诺福韦转换为以阿巴卡韦为基础的抗逆转录病毒疗法(无论是否联用阿扎那韦)对肾功能的影响。
J Int AIDS Soc. 2016 Sep 9;19(1):20995. doi: 10.7448/IAS.19.1.20995. eCollection 2016.
6
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.阿巴卡韦/拉米夫定或替诺福韦/恩曲他滨联合洛匹那韦/利托那韦用于初始HIV治疗的随机、双盲、安慰剂对照、多中心试验。
AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2.
7
Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.对接受含富马酸替诺福韦二吡呋酯单片复方制剂治疗的HIV感染患者的肾脏和骨骼安全性进行的真实世界评估。
PLoS One. 2016 Dec 12;11(12):e0166982. doi: 10.1371/journal.pone.0166982. eCollection 2016.
8
Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.在美国,多替拉韦(DTG)联合阿巴卡韦/拉米夫定(ABC/3TC)与依非韦伦/替诺福韦酯/恩曲他滨(EFV/TDF/FTC)用于初治HIV-1感染的成本效益分析
J Med Econ. 2015;18(10):763-76. doi: 10.3111/13696998.2015.1046878.
9
Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.基于艾滋病临床试验组5202临床试验,对替诺福韦/恩曲他滨及阿巴卡韦/拉米夫定联合依法韦仑或阿扎那韦/利托那韦用于英国初治HIV-1感染成人患者进行成本效益分析。
HIV Med. 2016 Aug;17(7):505-15. doi: 10.1111/hiv.12349. Epub 2015 Dec 9.
10
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.接受不同利托那韦增强型蛋白酶抑制剂与富马酸替诺福韦二吡呋酯或阿巴卡韦治疗的HIV感染受试者的估计肾小球滤过率轨迹
Medicine (Baltimore). 2016 May;95(22):e3780. doi: 10.1097/MD.0000000000003780.

引用本文的文献

1
Six month incidence of major adverse cardiovascular events among adults with HIV in northern Tanzania: a prospective observational study.坦桑尼亚北部 HIV 感染者主要不良心血管事件的 6 个月发生率:一项前瞻性观察研究。
BMJ Open. 2023 Nov 19;13(11):e075275. doi: 10.1136/bmjopen-2023-075275.